BeOne Medicines Ltd. (ONC) Stock
ONC has an Alpha Score of 36 out of 100 (weak), computed on Apr 15, 2026 from 3 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported ONC in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $406.23M. Company insiders reported 0 open-market buys and 53 sales on SEC Form 4 in the 90 days to Oct 21, 2026. Its trailing P/E ratio is 65.9 and its net margin 10.0% (key statistics as of Oct 22, 2026).
What is ONC's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Apr 15, 2026 · 189 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ONC?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.43M | $406.23M | +38% |
| Millennium Management Israel Englander | 543K | $154.83M | +165% |
| Marshall Wace | 178K | $50.72M | +3% |
| Renaissance Technologies Jim Simons (founder) | 102K | $29.06M | +56% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are BeOne Medicines Ltd. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 13, 26 | Wang Xiaodong | Director | SELL | 7.2K | $2.5M |
| Oct 13, 26 | Wang Xiaodong | Director | SELL | 10.4K | $3.6M |
| Oct 13, 26 | Wang Xiaodong | Director | SELL | 5.7K | $2.0M |
| Oct 13, 26 | Wang Xiaodong | Director | SELL | 6.6K | $2.3M |
| Oct 13, 26 | Wang Xiaodong | Director | SELL | 1.3K | $445K |
| Sep 30, 26 | Lee Chan Henry | SVP, General Counsel | SELL | 1.1K | $418K |
| Sep 28, 26 | Wang Xiaodong | Director | SELL | 160 | $57K |
| Sep 28, 26 | Wang Xiaodong | Director | SELL | 120 | $43K |
| Sep 28, 26 | Wang Xiaodong | Director | SELL | 40 | $14K |
| Sep 28, 26 | Wang Xiaodong | Director | SELL | 2.2K | $809K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are ONC's key statistics?
Key statistics as of Oct 22, 2026
How does ONC's valuation compare with the Healthcare sector?
| Metric | ONC | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 65.9 | 27.0 | 75 |
| Net margin | 9.97% | 9.40% | 92 |
| Return on equity | 13.33% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
ONC price chart
Powered by TradingViewWhat does BeOne Medicines Ltd. do?
BeOne Medicines, Ltd. American Depositary Receipt represents ownership in BeOne Medicines Ltd., a Switzerland-domiciled global oncology company headquartered in Cambridge, Massachusetts with corporate operations there and primary offices in Basel, Switzerland. The company discovers, develops, and commercializes innovative cancer treatments aimed at hematologic malignancies and solid tumors, including blood cancers, lung, breast, gastrointestinal, and rare cancers. Its portfolio features approved therapies like Brukinsa (zanubrutinib), a Bruton's tyrosine kinase inhibitor, and Tevimbra (tislelizumab), a PD-1 inhibitor used in combination regimens for various indications. BeOne Medicines advances a broad pipeline encompassing small molecules, monoclonal antibodies, antibody-drug conjugates, cell therapies, gene therapies, and novel inhibitors such as BCL2, CDK, KRAS, and PRMT5 targets. With one of the largest oncology research teams worldwide, it conducts global clinical trials internally without reliance on contract research organizations, operating across six continents in over 45 countries to enhance patient access to transformative medicines. Founded in 2010, BeOne Medicines maintains strategic partnerships with leading pharmaceutical firms to bolster its development and commercialization efforts in the competitive oncology market.